Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NateraMEX:NTRA 60 Days Inventory is 25.81 as of Mar. 2026, which is 4% above its 10-year median of 24.90. GuruFocus rates MEX:NTRA with a GF Score™ of 60/100 and a GF Value™ of MXN2,983.49 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 179 Medical Diagnostics & Research companies, Natera ranks better than 79.89% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Natera's Average Total Inventories for the
three
months ended in Mar. 2026 was MXN1,254 Mil. Natera's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN4,433 Mil.
Hence, Natera's Days Inventory for the
three
months ended in Mar. 2026 was 25.81.
The historical rank and industry rank for Natera's Days Inventory or its related term are showing as below:
MEX:NTRA'
s Days Inventory Range Over the Past 10 Years
Min: 19.53 Med: 24.9 Max: 29.06
Current: 25.77
During the past 13 years, Natera's highest Days Inventory was 29.06. The lowest was 19.53. And the median was 24.90.
MEX:NTRA's Days Inventory is ranked better than 79.89% of 179
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.04
vs MEX:NTRA: 25.77
Natera's Days Inventory
increased
from Mar. 2025 (23.66) to Mar. 2026 (25.81).
It might indicate that Natera's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Natera's Inventory Turnover for the
three
months ended in Mar. 2026 was 3.54.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Natera's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.10.
Natera (MEX:NTRA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Natera's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Natera's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Natera Days Inventory Related Terms
Natera Days Inventory Historical Data
* Premium members only.
The historical data trend for Natera's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NTRA vs WAT, A, IQV: Days Inventory Comparison
For the Diagnostics & Research subindustry, Natera's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Days Inventory distribution charts can be found below:
* The bar in red indicates where Natera's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natera (MEX:NTRA) has a Days Inventory of 25.81 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Natera and its competitors. This is near median its historical median of 24.90. Over the past decade, Natera's Days Inventory has ranged from 19.53 to 29.06. According to the industry distribution chart, Natera ranks #36 out of 179 companies in the Medical Diagnostics & Research industry, placing it in the top 20.1%.
Is Natera's Days Inventory too high?
Natera's current Days Inventory of 25.81 is near median its 10-year median of 24.90. Over the past 10 years, this metric has ranged from a low of 19.53 to a high of 29.06. The Medical Diagnostics & Research industry median Days Inventory is 65.04. Natera's value of 25.81 is 60.3% below this industry median. Based on the distribution chart, Natera ranks #36 out of 179 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Natera has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Natera's Days Inventory compare to WAT and A?
According to the Medical Diagnostics & Research industry distribution chart, Natera ranks #36 out of 179 companies for Days Inventory. This places Natera in the top 20% of its industry — outperforming the majority of peers. The industry median Days Inventory is 65.04. Natera's value of 25.81 is 60.3% below this benchmark. Historically, Natera's own Days Inventory has ranged from 19.53 to 29.06 over the past decade. While the company's 10-year median is 24.90 vs. the industry median of 65.04, Natera has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 65.04, based on 179 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Natera's current Days Inventory of 25.81 is 60.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Natera and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 65.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natera's current Days Inventory is 25.81, which is near median its own 10-year median of 24.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natera stock overvalued right now?
Based on GuruFocus' analysis, Natera (MEX:NTRA) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,983.49, compared to a current price of MXN3,905.00 — trading 30.9% above its estimated fair value. The current Days Inventory is 25.81, which is near median its 10-year median of 24.90 and 60.3% below the Medical Diagnostics & Research industry median of 65.04. Natera's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Natera (MEX:NTRA), the current Days Inventory is 25.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natera (MEX:NTRA) Overvalued in 2026?
Based on GuruFocus' analysis, Natera stock appears to be overvalued.
The current stock price of MXN3,905.00 is trading 30.9% above its estimated GF Value™ of MXN2,983.49.
GuruFocus considers Natera to be Significantly Overvalued.
Key valuation signals for MEX:NTRA:
Days Inventory: 25.81 (near median its 10-year median of 24.90)
GF Value™: MXN2,983.49 vs. price of MXN3,905.00 (30.9% above fair value)
Industry Position: 60.3% below the Medical Diagnostics & Research median (#36 of 179)
No single metric tells the full story. See the MEX:NTRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
60GF Score
Get the complete analysis for MEX:NTRA
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NTRA has been successfully added to your 
